NCCN® Recommendation

National Comprehensive Cancer Network® (NCCN®) recommendation for poor-risk patients with advanced RCC1

 

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate1
This category 1 recommendation is based on published results of the phase 3 Global ARCC study (Hudes et al 20072).

REFERENCES
  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer V.3.2015. © National Comprehensive Cancer Network, Inc 2014. All rights reserved. Accessed January 13, 2015. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
  2. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281.